Diabesity: an old term, a modern challenge — multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes
Journal of Pharmacy & Pharmaceutical Sciences · 2026
DOI: 10.3389/jpps.2026.17560 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2026. Verfasst von Karolina Hoffmann und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Poznań, Poland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Anti-Obesity Agents, Diabesity, Hypoglycemic Agents. Die Arbeit nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM) and obesity are closely interconnected but heterogeneous conditions in which treatment response, safety, body weight, glycemic control, and long-term clinical outcomes vary substantially between individuals. This narrative review evaluates emerging anti-obesity pharmacotherapy in patients with coexisting T2DM and obesity and examines the translational role of multi-omics in future precision treatment selection. Distinct from reviews focused primarily on obesity pharmacotherapy or omics-based disease stratification, the present review emphasizes the interface between contemporary drug mechanisms, T2DM-associated metabolic heterogeneity, candidate molecular signatures, and the level of evidence required for clinically actionable prescribing. We summarize evidence for approved and investigational oral incretin therapies, dual and triple receptor agonists, amylin-based strategies, established antidiabetic drugs, and adjunctive approaches targeting body composition. Throughout the review, we distinguish established clinical evidence from mechanistic rationale, candidate biomarkers, exploratory associations, and hypothetical future precision applications. We also separate metabolic efficacy endpoints, such as body weight and HbA1c, from intermediate cardiometabolic risk markers and from cardiovascular or kidney outcomes demonstrated in dedicated outcome trials. At present, no genomic, metabolomic, lipidomic, proteomic, microbiome, or integrated multi-omics signature has been clinically validated to select a specific anti-obesity medication for patients with T2DM and obesity. Major unresolved issues include the need for prospective biomarker validation, direct comparative trials, standardized assays, externally validated and calibrated prediction models, preservation of skeletal muscle health and physical function, long-term safety, treatment durability, affordability, and equitable implementation. Multi-omics should therefore be viewed as an investigational framework for generating and testing precision-treatment hypotheses rather than as a basis for routine prescribing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Poznań, Poland.
- Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Poznań, Poland.
- Health Care Complex in Ostrów Wielkopolski, Inpatient Treatment, Department of Internal Medicine - Ward B, Ostrów Wielkopolski, Poland.
- Promise Department, School of Medicine, University of Palermo, Palermo, Italy.
- Department of Pharmaceutical Chemistry, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
- Department of Clinical Pharmacy and Pharmacology, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates.
Zitieren
APA
Hoffmann, K., Pucek, W. F., Skrzypek, W., Kierzkowski, F., Ratajczak, P., Maggio, V., Rizzo, M., El-Tanani, M., Rabbani, S. A., Bhongade, B., Satyam, S. M., Talath, S., Rangraze, I. R., Wali, A. F., Ibraheem, W., El-Tanani, Y., Ispas, S., Bryl, W., & Paczkowska, A. (2026). Diabesity: an old term, a modern challenge — multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2026.17560
Vancouver
Hoffmann K, Pucek WF, Skrzypek W, Kierzkowski F, Ratajczak P, Maggio V, et al. Diabesity: an old term, a modern challenge — multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes. Journal of Pharmacy & Pharmaceutical Sciences. 2026. doi:10.3389/jpps.2026.17560
BibTeX
@article{Hoffmann2026,
author = {Hoffmann, Karolina and Pucek, Weronika Faustyna and Skrzypek, Wiktoria and Kierzkowski, Filip and Ratajczak, Piotr and Maggio, Viviana and Rizzo, Manfredi and El-Tanani, Mohamed and Rabbani, Syed Arman and Bhongade, Bhoomendra and Satyam, Shakta Mani and Talath, Sirajunisa and Rangraze, Imran Rashid and Wali, Adil Farooq and Ibraheem, Walaa and El-Tanani, Yahia and Ispas, Sorina and Bryl, Wiesław and Paczkowska, Anna},
title = {Diabesity: an old term, a modern challenge — multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes},
journal = {Journal of Pharmacy & Pharmaceutical Sciences},
year = {2026},
doi = {10.3389/jpps.2026.17560}
}
EUVIMED